Earnings History Data for Myriad Genetics, Inc. (MYGN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Myriad Genetics, Inc.

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-11-2024	AH		MYGN	Myriad Genetics, Inc.	1,600	-0.06	-0.07	-0.17	Myriad Genetics Non-GAAP EPS of $0.06 beats by $0.04, revenue of $213.3M beats by $2.51M [11/7/2024 4:36 PM]	17.43	-0.24 (-1.36%)	17.67	0.0 (0.00%)	15.99 - 29.30	852,800	1,110,000	67,115
Myriad Genetics Non-GAAP EPS of $0.06 beats by $0.04, revenue of $213.3M beats by $2.51M [11/7/2024 4:36 PM] Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance [2024-11-07 04:05PM]
06-08-2024	AH		MYGN	Myriad Genetics, Inc.	2,500	-0.10	-0.10	-0.21	Myriad Genetics Non-GAAP EPS of $0.05 beats by $0.06, revenue of $211.5M beats by $6.49M [8/6/2024 5:28 PM]	26.73	0.77 (2.97%)	25.96	0.0 (0.00%)	13.82 - 28.90	1,107,815	990,000	33,184
Myriad Genetics Non-GAAP EPS of $0.05 beats by $0.06, revenue of $211.5M beats by $6.49M [8/6/2024 5:28 PM]
07-05-2024	AH		MYGN	Myriad Genetics	1,739	-0.14	-0.11	0.00	Myriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.2M beats by $8.95M [5/7/2024 4:36 PM]	23.89	4.11 (20.78%)	23.40	3.62 (18.30%)	13.82 - 24.21	2,329,834	790,000	2,311
Myriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.2M beats by $8.95M [5/7/2024 4:36 PM] Myriad Genetics surges 17% as Street applauds 2024 guidance, Q1 results [5/8/2024 11:46 AM]
27-02-2024	AH		MYGN	Myriad Genetics, Inc.	1,870	-0.07	-0.05	-0.20	Myriad Genetics Non-GAAP EPS of $0.04 beats by $0.03, revenue of $196.6M beats by $1.97M [2/27/2024 4:38 PM]	21.64	-1.86 (-7.91%)	23.25	-0.25 (-1.06%)	13.82 - 24.21	961,874	550,000	804
Myriad Genetics Non-GAAP EPS of $0.04 beats by $0.03, revenue of $196.6M beats by $1.97M [2/27/2024 4:38 PM]
06-11-2023	AH		MYGN	Myriad Genetics, Inc.	1,310	-0.17	-0.16	-0.27	Myriad Genetics Non-GAAP EPS of -$0.03 beats by $0.05, revenue of $191.9M beats by $12.8M [11/6/2023 4:17 PM]	17.77	1.43 (8.75%)	16.00	-0.34 (-2.08%)	13.82 - 24.21	738,924	630,000	12,841
Myriad Genetics Non-GAAP EPS of -$0.03 beats by $0.05, revenue of $191.9M beats by $12.8M [11/6/2023 4:17 PM]
03-08-2023	AH		MYGN	Myriad Genetics, Inc.	1,780	-0.21	-0.18	-0.06	Myriad Genetics Non-GAAP EPS of -$0.08 beats by $0.01, revenue of $183.5M misses by $3.36M [8/3/2023 4:28 PM]	19.29	-1.47 (-7.08%)	20.00	-0.76 (-3.66%)	13.92 - 28.18	1,035,113	410,000	1,053
Myriad Genetics Non-GAAP EPS of -$0.08 beats by $0.01, revenue of $183.5M misses by $3.36M [8/3/2023 4:28 PM]
03-05-2023	AH	After the close (May 3)	MYGN	Myriad Genetics, Inc.	1,770	-0.28	-0.28	-0.14	Myriad Genetics reports Q1 results, narrows FY 2023 guidance [5/3/2023 4:38 PM]	21.00	-0.89 (-4.07%)	21.89	0.0 (0.00%)	13.92 - 28.18	590,131	440,000	142,260
Myriad Genetics reports Q1 results, narrows FY 2023 guidance [5/3/2023 4:38 PM]
28-02-2023	AH	After the close (Feb 28)	MYGN	Myriad Genetics, Inc.	1,500	-0.20	-0.27	-0.11	Myriad Genetics Non-GAAP EPS of -$0.12 beats by $0.05, revenue of $177.8M beats by $8.38M [2/28/2023 4:38 PM]	21.49	2.57 (13.58%)	18.92	0.0 (0.00%)	13.92 - 28.18	796,964	660,000	52,879
Myriad Genetics Non-GAAP EPS of -$0.12 beats by $0.05, revenue of $177.8M beats by $8.38M [2/28/2023 4:38 PM] Myriad Genetics surges 15% amid strong 2023 guidance, quarterly top and bottom line beats [3/1/2023 1:39 PM]
01-11-2022	PM	7:05 AM ET (Nov 1)	MYGN	Myriad Genetics, Inc.	1,680	-0.27	-0.15	-0.12	Myriad Genetics Non-GAAP EPS of -$0.19 misses by $0.11, revenue of $156.4M misses by $13.97M, updates FY guidance [11/1/2022 9:12 AM]	17.51	-3.23 (-15.57%)	18.00	-2.74 (-13.21%)	15.94 - 32.00	972,091	470,000	1,947
Myriad Genetics Q3 2022 Earnings Preview [10/31/2022 12:14 PM] Myriad Genetics Non-GAAP EPS of -$0.19 misses by $0.11, revenue of $156.4M misses by $13.97M, updates FY guidance [11/1/2022 9:12 AM] Myriad Genetics falls 19% after lowering full-year guidance, Q3 misses [11/1/2022 11:52 AM] Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member [Oct-31-22 04:30PM]
04-08-2022	PM	4:05 PM ET (Aug 4)	MYGN	Myriad Genetics, Inc.	1,960	-0.06	-0.09	0.03	Myriad Genetics GAAP EPS of $0.04 beats by $0.19, revenue of $179.3M beats by $9.25M [8/4/2022 7:48 AM]	27.40	1.47 (5.67%)	3.92	-0.40 (-9.26%)	16.02 - 36.95	633,692	560,000	51,552
Myriad Genetics Q2 2022 Earnings Preview [8/3/2022 12:10 PM] Myriad Genetics GAAP EPS of $0.04 beats by $0.19, revenue of $179.3M beats by $9.25M [8/4/2022 7:48 AM] Myriad Genetics Reports Second Quarter Financial Results [Aug-04-22 07:05AM]
05-05-2022	PM	4:05 PM ET (May 5)	MYGN	Myriad Genetics, Inc.	1,700	-0.14	-0.15	-0.16	Myriad Genetics Non-GAAP EPS of -$0.03 beats by $0.06, revenue of $164.9M beats by $8.81M [5/5/2022 9:06 AM]	21.60	-0.25 (-1.14%)	21.85	0.0 (0.00%)	20.26 - 36.95	697,830	510,791	23,295
Myriad Genetics Q1 2022 Earnings Preview [5/4/2022 1:53 PM] Myriad Genetics Non-GAAP EPS of -$0.03 beats by $0.06, revenue of $164.9M beats by $8.81M [5/5/2022 9:06 AM] Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates [May-04-22 06:15PM] Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference [May-04-22 04:05PM] Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022 [May-05-22 09:00AM] Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates [May-05-22 09:45AM]
24-02-2022	PM	4:05 PM ET (Feb 24)	MYGN	Myriad Genetics, Inc.	2,050	-0.11	-0.15	-0.19	Myriad Genetics Non-GAAP EPS of -$0.02 beats by $0.04, revenue of $160.8M misses by $1.41M [2/24/2022 9:11 AM]	24.96	1.16 (4.87%)	0.0	0.0 (0.00%)	0.0 - 0.0	323,537	0	0
Myriad Genetics FQ2 2021 Earnings Preview [2/23/2022 5:35 PM] Myriad Genetics Q4 2021 Earnings Preview [2/23/2022 2:12 PM] Myriad Genetics Non-GAAP EPS of -$0.02 beats by $0.04, revenue of $160.8M misses by $1.41M [2/24/2022 9:11 AM] New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test [Feb-23-22 04:30PM] Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives [Feb-24-22 09:00AM] Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates [Feb-24-22 10:25AM]
02-11-2021	PM	4:05 PM ET (Nov 2)	MYGN	Myriad Genetics, Inc.	2,500	-0.12	-0.12	-0.19	Myriad Genetics EPS misses by $0.01, beats on revenue [11/2/2021 8:37 AM]	30.80	-0.39 (-1.25%)	30.80	0.0 (0.00%)	12.55 - 36.95	464,438	430,000	7,516
Myriad Genetics Q1 2021 Earnings Preview [11/1/2021 5:35 PM] Myriad Genetics Q3 2021 Earnings Preview [11/1/2021 1:41 PM] Myriad Genetics EPS misses by $0.01, beats on revenue [11/2/2021 8:37 AM] Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans [Nov-02-21 08:30AM] Myriad Genetics (MYGN) Reports Q3 Loss, Tops Revenue Estimates [Nov-02-21 09:45AM] Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript [Nov-02-21 08:01PM]
03-08-2021	PM	7:00 AM ET (Aug 3)	MYGN	Myriad Genetics, Inc.	2,440	0.03	-0.20	-0.33	Myriad Genetics EPS beats by $0.22, beats on revenue [8/3/2021 7:31 AM]	35.26	4.40 (14.26%)	30.86	0.0 (0.00%)	11.76 - 35.34	2,011,235	420,000	10,635
Myriad Genetics Q2 2021 Earnings Preview [8/2/2021 2:27 PM] Myriad Genetics launches new version of MyRisk Hereditary Cancer Test [8/2/2021 7:29 AM] Myriad Genetics EPS beats by $0.22, beats on revenue [8/3/2021 7:31 AM] Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries [Aug-02-21 07:05AM] Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans [Aug-03-21 07:05AM] Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates [Aug-03-21 08:35AM]
03-05-2021	AH	4:05 PM ET (May 3)	MYGN	Myriad Genetics, Inc.	2,330	-0.16	-0.22	-0.16	Myriad Genetics EPS beats by $0.09, beats on revenue [5/3/2021 4:49 PM]	31.61	1.21 (3.98%)	30.40	0.0 (0.00%)	10.54 - 33.97	667,437	490,000	199,893
Myriad Genetics gains as Q1 financials indicate a return to growth [5/4/2021 8:07 AM] Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmunes Vectra Testing Business to Labcorp [May-03-21 07:05AM] Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day [May-03-21 07:00AM] Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives [May-03-21 04:05PM] Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates [May-03-21 06:35PM] Myriad Genetics Stock Is Jumping. Earnings Were Great. [May-04-21 08:07AM]
23-02-2021	AH	4:05 PM ET (Feb 23)	MYGN	Myriad Genetics, Inc.	2,360	-0.19	-0.23	0.15	Myriad Genetics EPS in-line, beats on revenue [2/23/2021 4:37 PM]	30.07	1.04 (3.58%)	29.03	0.0 (0.00%)	9.24 - 31.59	643,516	701,828	18,326
Myriad Genetics EPS in-line, beats on revenue [2/23/2021 4:37 PM] Myriad Genetics Inc (MYGN) Q2 2021 Earnings Call Transcript [Feb-23-21 08:30PM]
09-11-2020	PM	4:05 PM ET (Nov 9)	MYGN	Myriad Genetics, Inc.	1,060	-0.19	-0.42	-0.03	Myriad Genetics EPS beats by $0.15, beats on revenue [11/9/2020 8:14 AM]	17.02	0.83 (19.10%)	14.95	0.66 (4.62%)	9.24 - 30.13	1,137,872	470,371	6,667

13-08-2020	AH	4:05 PM ET (Aug 13)	MYGN	Myriad Genetics, Inc.	926.71	-0.33	-0.49	0.30	Myriad Genetics EPS beats by $0.18, beats on revenue [8/13/2020 4:11 PM]	12.35	-1.03 (-7.70%)	13.40	0.02 (0.15%)	9.24 - 35.29	1,548,779	650,814	12,773

05-05-2020	AH	4:05 PM ET (May 5)	MYGN	Myriad Genetics, Inc.	1,100	-0.16	-0.10	0.34	Myriad Genetics EPS misses by $0.09, misses on revenue [5/5/2020 4:15 PM]	14.82	-0.43 (-2.82%)	0.0	0.0 (0.00%)	9.24 - 48.40	1,598,918	1,109,140	0